Alkem share price today

Alkem Laboratories Ltd's share price was ₹5,216.50 at the close on 4 November 2026. It has been falling for 5 weeks. That is 2.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹4,947 and ₹5,837, and at that close it sat 30% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Alkem Laboratories Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row.

Over the last 11 years the share price moved +282% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

One change stood out: revenue up on a year earlier for 7 quarters in a row.

1. Revenue up on a year earlier for 7 quarters in a row

   In the June 2026 quarter revenue was ₹3,740 crore, +10.9% on a year earlier.

   Why: Revenue rose because branded India medicines grew at a double digit rate and smaller non-US markets grew fast. Trade generics were flat and US volumes were weak, but currency changes made US sales look better.

   Next results: check whether trade generics recover and help domestic growth.

   From the earnings call on 14 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Alkem reported revenue of ₹3,740 crore, up 10.9% from ₹3,371 crore a year earlier, and a profit of ₹521 crore, down 22.0% from ₹668 crore.

Alkem results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Alkem's management discussed these results on a call held on 14 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Alkem closed at ₹5,216.50 on 4 November 2026, down 8.0% from ₹5,668.50 a year earlier (7 November 2025) and up 43.0% over five years. Its highest weekly close since March 2016 was ₹6,366.25 on 13 September 2024.

Alkem share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Alkem closed at ₹5,216.50, up 2.0% on the week and down 0.1% on the month. 14 Aug 2026: Alkem held its results call for April to June 2026. Management guided: India FY27 growth could end close to 12%; trade-generics growth of mid-single digits was described as acceptable over the next 1-2 years.

Earlier

• 7 Aug 2026: ex-date for a dividend of ₹10 a share.
• Results for April to June 2026: Revenue up 10.9% and profit down 22.0% on a year earlier.
• 20 Feb 2026: ex-date for an interim dividend of ₹43 a share.

Alkem paid ₹53 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 1.02% at the ₹5,216.50 close on 4 November 2026. The last was a dividend of ₹10 a share, ex-date 7 August 2026.

Alkem dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Alkem Laboratories Ltd paid out 28% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 14 August 2026, Alkem's management guided: India FY27 growth could end close to 12%; trade-generics growth of mid-single digits was described as acceptable over the next 1-2 years.

“The OAI status of the Daman plant is a concern, but we do not see it impacting our business because nothing has stopped and the observations have been addressed.”Sandeep Singh, on the call for April to June 2026

What management guided

• Gross margin maintained at 66.5-67% for the balance of FY27; API price increases expected to pressure later quarters.
• US FY27 growth expected at high-single-digit to mid/high-single-digit, aided by currency; Daman OAI expected to have no business impact this year and resolve in 6-12 months.
• Consolidated FY27 tax rate expected at approximately 30-32%; loss-making US S&G entities are not generating deferred tax assets.
• Enzene US CDMO revenue expected to begin in FY28; break-even ruled out within the next 12 months, requiring annualized revenue of 25-30 million dollars; scale-up capital spending not expected this year.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 14 August 2026.

When Alkem reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Trade-generics primary sales recovery - check whether tighter DSO and inventory actions reverse the domestic growth drag.

Alkem is on 2 of our India lists: Small & mid cap stocks and Pharma stocks.

Alkem Laboratories Ltd earned ₹521 Cr of net profit in the Jun 2026 quarter, −22.0% on the same quarter a year earlier. Full-year FY26 profit was ₹2,351 Cr. Over 10 years profit has grown 12.1% a year on average. That is 13.9% of the quarter's revenue. The same quarter a year earlier earned ₹668 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹2,351 Cr (+6.1% on the year before).

Why profit moved: revenue changed +10.9% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −7.8% and revenue +13.4%. Profit is growing slower than sales: rising costs are taking part of the growth.

Alkem Laboratories Ltd reported ₹3,740 Cr of revenue in the Jun 2026 quarter, +10.9% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 10 years it has grown 11.6% a year on average. The last full year, FY26, came in at ₹14,712 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹15,081 Cr.

FY26 revenue was ₹14,712 Cr, +13.5% on the year before.

Recent pace: the last four quarters grew +13.4% on average, against 11.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +13.4%, against +8.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −5.5%, against +3.1% a year (rolling over).

Alkem Laboratories Ltd's operating margin was 20.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 12.0% and 22.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −1.4 percentage points on the year while gross margin changed +2.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 91% of Alkem Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,963 Cr of operating cash against ₹2,351 Cr of profit. After ₹1,135 Cr of spending on assets, ₹828 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 91% of profit came in as cash: the cash cycle got 44 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 2.1× depreciation over three years. The next section checks what that spending is building.

Alkem Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 152 days in FY26, down from 196 days in FY21. It spent ₹2,185 Cr on assets over the last 3 years. Customers take 74 days to pay, and stock sits for 239 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹14,712 Cr, each day of that cycle ties up about ₹40.3 Cr, so roughly ₹6,127 Cr is tied up in the business at any time.

FY26: customers took 74 days to pay and stock sat for 239 days, about 7.9 months of sales sitting as stock, for a full cycle of 152 days, shorter than FY21's 196.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 239 days. Customers pay about 74 days after that. Suppliers are paid at 161 days. Together that makes the 152-day cycle.

Spending on assets: ₹2,185 Cr over the last 3 years, against ₹1,038 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹282 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Alkem Laboratories Ltd's P/E is 27.4×, in the middle of its own history: higher than 42% of past readings. Its usual P/E (the middle reading) is 28.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹180.45.